• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » BioDelivery Sciences appoints Thomas W. D'Alonzo to board of directors

BioDelivery Sciences appoints Thomas W. D'Alonzo to board of directors

April 30, 2013
CenterWatch Staff

BioDelivery Sciences International, a specialty pharmaceutical company, has appointed Thomas W. D'Alonzo to the company's board of directors.

Previously, D'Alonzo served on the BDSI board of directors from August 2006 through June 2008. He has held numerous high-level executive positions and board appointments within both large and specialty pharmaceutical companies. D'Alonzo has been a member of the board of directors at Salix Pharmaceuticals since May 2000 and chairman of the board since June 2010. He  has also previously served on the board of directors of Plexigen, DARA BioSciences and Amarillo Biosciences.

D'Alonzo's extensive pharmaceutical industry background also includes a number of executive positions, including CEO at biotechnology companies DARA BioSciences and GenVec, and president and COO at PPD. Early in his career and over a 10 year period, he held positions of increasing responsibility within Glaxo, the U.S. division of GlaxoSmithKline, including serving as president from 1988 to 1993. D'Alonzo has also been an independent pharmaceutical industry consultant for a number of years.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing